Related Experiment Video
Updated: Aug 18, 2026

A Laser-induced Mouse Model of Chronic Ocular Hypertension to Characterize Visual Defects
Published on: August 14, 2013
Short-Term IOP Lowering Effect on the Contralateral Eye After 180° Selective Laser Trabeculoplasty
Rasha Eltanamly1, Riham S H M Allam1, Mina M Habib1
1Ophthalmology Department, Kasr Alainy School of Medicine, Cairo University, Giza, Egypt.
Purpose:
To assess the contralateral intraocular pressure (IOP) lowering effect following 180° selective laser trabeculoplasty (SLT) in the untreated eye and to compare IOP reduction between treated and untreated eyes.
Methods:
This prospective, interventional, non-randomized study included 40 treated eyes and 40 fellow eyes with open-angle glaucoma, and insufficient IOP control. Preoperative and postoperative IOP were measured using a Goldmann applanation tonometer. Subjects were treated with 50 non-overlapping laser pulses over 180° of the angle. IOP was measured bilaterally before SLT and at 1 week, 1 month, 3 months, and 6 months thereafter.
Results:
IOP changes were assessed in both the treated and contralateral eyes, revealing a significant reduction throughout the six-month follow-up. In the treated eye, IOP decreased from 20.23 ± 4.74 mmHg pre-SLT to 15.58 ± 3.13 mmHg (p < .001), while the contralateral eye decreased from 18.28 ± 3.87 mmHg to 15.88 ± 3.89 mmHg (p = .004) at the last follow-up visit. The treated eye consistently showed a greater percentage reduction, with contralateral effects of 65.47%, 68.14%, 60.32%, and 58.64% at 1 week, 1 month, 3 months, and 6 months, respectively. A strong positive correlation was found between IOP reduction in the contralateral eye and the corresponding treated eye (r = 0.718, p < .001), and a moderate correlation with the treated eye's baseline IOP (r = 0.368, p = .020).
Conclusion:
A statistically significant contralateral IOP reduction was observed following 180° SLT.
Related Concept Videos
Angle Closure Glaucoma: Treatment
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Ophthalmic Drug Delivery Systems
Glaucoma: Overview